In a significant advancement for veterinary medicine, Fidelis Animal Health has introduced a groundbreaking pain management solution for animals commonly used in research settings. The FDA has recently approved Ethiqa XR, an extended-release buprenorphine injectable suspension, for use in mice, rats, ferrets, and now, non-human primates (NHPs). This approval marks a pivotal step in enhancing animal welfare by providing effective and prolonged pain relief post-procedures.
Ethiqa XR, with a concentration of 1.3 mg/mL, leverages a patented lipid-based technology, Fidelipid LAI, to deliver up to 72 hours of clinical analgesia from a single subcutaneous injection. This innovative formulation not only simplifies the management of post-procedural pain but also aligns with the high standards of efficacy, safety, and quality that veterinarians expect.
Michael Wells, the CEO of Fidelis Animal Health, expressed his enthusiasm about the new indication for NHPs, highlighting the company’s commitment to advancing veterinary care. “We are excited to bring this new NHP indication to veterinarians. Now, these caregivers have a three-day pain reliever that meets their high expectations for efficacy, safety, and quality,” he stated.
The development of Ethiqa XR is backed by robust scientific research, including studies that have demonstrated its safety and effectiveness. Notable research published in scientific journals such as ‘Scientific Reports’ and ‘Journal of Medical Primatology’ provides a solid foundation for the use of Ethiqa XR in clinical settings. These studies underscore the drug’s ability to maintain consistent and controlled pain relief, which is crucial for the recovery and well-being of the animals.
Veterinarians interested in this advanced pain management option can find more detailed information, including important safety guidelines and warnings, on the Ethiqa XR website. This resource is designed to assist veterinary professionals in making informed decisions that enhance the quality of care for animal patients.
The introduction of Ethiqa XR represents a significant stride forward in veterinary pharmacology, offering a scientifically validated, FDA-cleared solution that upholds the highest standards of animal health and welfare.
